ARCA biopharma Inc (ABIO)

1.18
0.03 2.17
NASDAQ : Health Care
Prev Close 1.15
Open 1.15
Day Low/High 1.15 / 1.19
52 Wk Low/High 2.73 / 8.40
Volume 1.13K
Avg Volume 187.30K
Exchange NASDAQ
Shares Outstanding 14.40M
Market Cap 16.56M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ARCA Biopharma Announces Second Quarter 2017 Financial Results And Provides Business Update

ARCA Biopharma Announces Second Quarter 2017 Financial Results And Provides Business Update

Outcome of GENETIC-AF Data and Safety Monitoring Board Phase 2B Interim Efficacy Analysis and Recommendation Anticipated in August 2017

ARCA Biopharma Announces First Quarter 2017 Financial Results And Provides Business Update

Outcome of GENETIC-AF Phase 2B Interim Efficacy Analysis Anticipated in September 2017

Dr. Michael Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 200 th patient has...

ARCA Biopharma To Present At The Planet MicroCap Showcase 2017 Investor Conference

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a...

Dr. Michael Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year...

ARCA Biopharma Announces 175th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 175 th patient has...

Anders Hove, M.D. (Photo: Business Wire)

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Anders Hove, M.

Dr. Michael Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

Dr. Michael Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 150 th patient has...

ARCA Biopharma To Present At Biotech Showcase 2017

ARCA Biopharma To Present At Biotech Showcase 2017

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a...

ARCA Biopharma Announces Third Quarter 2016 Financial Results And Provides Business Update

ARCA Biopharma Announces Third Quarter 2016 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2016, and provided...

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc.

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to the development of genetically-targeted therapies for cardiovascular diseases, today announced the randomization of...

ARCA Biopharma To Present At The Dawson James Securities Second Annual Growth Stock Conference

ARCA Biopharma To Present At The Dawson James Securities Second Annual Growth Stock Conference

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a...

ARCA Biopharma Named Winner Of Corporate LiveWire Healthcare And Lifesciences Innovation Award

ARCA Biopharma Named Winner Of Corporate LiveWire Healthcare And Lifesciences Innovation Award

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that is has been named as one...

ARCA Biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial

ARCA Biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 100 th patient has...

ARCA Biopharma Announces Second Quarter 2016 Financial Results And Provides Business Update

ARCA Biopharma Announces Second Quarter 2016 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2016, and provided a...

ARCA Biopharma Announces First Quarter 2016 Financial Results And Provides Business Update

ARCA Biopharma Announces First Quarter 2016 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a...

ARCA Biopharma Announces 75th Patient Enrolled In GENETIC-AF Phase 2B/3 Clinical Trial

ARCA Biopharma Announces 75th Patient Enrolled In GENETIC-AF Phase 2B/3 Clinical Trial

ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the 75 th patient has been enrolled in GENETIC-AF, a Phase 2B/3...

ARCA Biopharma Announces Fiscal Year 2015 Financial Results And Provides Business Update

ARCA Biopharma Announces Fiscal Year 2015 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2015, and provided a...

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today provided an update on GENETIC-AF, the Company's Phase 2B/3 clinical trial...

ARCA Biopharma To Present At The 27th Annual Piper Jaffray Healthcare Conference

ARCA Biopharma To Present At The 27th Annual Piper Jaffray Healthcare Conference

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it will make a presentation at the 27 th Annual Piper Jaffray...

ARCA Biopharma Announces Third Quarter 2015 Financial Results And Provides Business Update

ARCA Biopharma Announces Third Quarter 2015 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2015, and provided...

ARCA Biopharma CEO Michael Bristow To Present In Two Sessions At The American Heart Association Scientific Sessions 2015

ARCA Biopharma CEO Michael Bristow To Present In Two Sessions At The American Heart Association Scientific Sessions 2015

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Michael R.

4 Stocks Under $10 Making Big Up Moves on Big Volume

4 Stocks Under $10 Making Big Up Moves on Big Volume

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Gencaro™ Potential Efficacy Preventing Atrial Flutter In Heart Failure Paper To Be Presented At 2015 HFSA Annual Scientific Meeting

Gencaro™ Potential Efficacy Preventing Atrial Flutter In Heart Failure Paper To Be Presented At 2015 HFSA Annual Scientific Meeting

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper "Bucindolol Prevents Atrial Flutter via the Beta-1 389...

ARCA Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference

ARCA Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its Chief Operating Officer, Thomas A.

ARCA Biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments

ARCA Biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2015, and provided an...

ARCA Biopharma Announces Closing Of $37 Million Private Placement

ARCA Biopharma Announces Closing Of $37 Million Private Placement

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the closing of the previously announced private placement financing...